www.fdanews.com/articles/87175-vioquest-pharmaceutical-s-targeted-cancer-therapeutic-for-solid-tumors-begins-trials-at-moffitt-cancer-center
VIOQUEST PHARMACEUTICAL'S TARGETED CANCER THERAPEUTIC FOR SOLID TUMORS BEGINS TRIALS AT MOFFITT CANCER CENTER
May 30, 2006
VioQuest Pharmaceuticals, a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing
targeted cancer compounds, has initiated a Phase I/IIa clinical trial to assess the safety and dosing of VQD-002, triciribine-phosphate (TCN-P).
PR Leap